Dental follicle mesenchymal stem cell administration ameliorates muscle weakness in MuSK-immunized mice.

Ulusoy C. A., Zibandeh N., Yildirim S., TRAKAS N., ZISIMOPOULOU P., Kucukerden M., ...More

Journal of neuroinflammation, vol.12, pp.231, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 12
  • Publication Date: 2015
  • Doi Number: 10.1186/s12974-015-0451-0
  • Journal Name: Journal of neuroinflammation
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.231
  • Keywords: Myasthenia gravis, Muscle-specific kinase, Mesenchymal stem cells, Dendritic cells, Autoimmunity, AUTOIMMUNE MYASTHENIA-GRAVIS, TYROSINE KINASE MUSK, BONE-MARROW, CLINICAL-APPLICATIONS, SUPPRESSION, EXPRESSION, GAMMA
  • Istanbul University Affiliated: Yes


Background: Myasthenia gravis (MG) is an antibody-mediated autoimmune disease of the neuromuscular junction (NMJ), mostly associated with acetylcholine receptor (AChR) antibodies. Around 5-10 % of MG patients show antibodies to muscle-specific tyrosine kinase (MuSK). Mesenchymal stem cell (MSC) administration has been shown to ameliorate muscle weakness in the experimental autoimmune myasthenia gravis (EAMG) model induced by AChR immunization.